<DOC>
	<DOCNO>NCT00913120</DOCNO>
	<brief_summary>The purpose study examine superiority YM150 placebo evaluate dose-dependent response YM150 patient undergo elective total hip replacement surgery .</brief_summary>
	<brief_title>Prevention Venous Thromboembolism Patients Undergoing Elective Total Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Subjects schedule elective primary total hip replacement surgery Written inform consent obtain screen Subject history deep vein thrombosis and/or pulmonary embolism Subject hemorrhagic disorder and/or coagulation disorder Subject clinically important bleeding occur within 90 day prior screen visit Subject acute bacterial endocarditis , retinopathy , hypertension , thrombocytopenia Subject receive anticoagulants/antiplatelet agent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>YM150</keyword>
	<keyword>FXa inhibitor</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Anticoagulant</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Arthroplasty , replacement , hip</keyword>
</DOC>